Can-fite Biopharma (CANF) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$405,000.00

Revenue (quarter)

$202,000.00

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

$405,000.00

Gross margin

100.00%

Net income (trailing twelve months)

−$9.6M

Net income (quarter)

−$4.6M

Net income growth (year over year)

+5.64%

Net margin

−2358.77%

Return on equity

−211.37%

EPS (trailing twelve months)

−$5.84

Book value per share

$2.27

P/E (trailing twelve months)

—

Price to book

1.21

Debt to assets

39.73%

Payout ratio

—

Dividend yield

—

Company profile

Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.

• Is Can-fite Biopharma (CANF) profitable?

  No. Can-fite Biopharma reported a net loss of $9.6M over the trailing twelve months.

• How much revenue does Can-fite Biopharma (CANF) make?

  Can-fite Biopharma generated $405,000.00 in revenue over the trailing twelve months.

• How do I buy stock in Can-fite Biopharma (CANF)?

  CANF trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.